Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction
Background: As inflammation following ST-segment elevation myocardial infarction (STEMI) is both beneficial and deleterious, there is a need to find new biomarkers of STEMI severity.Objective: We hypothesized that the circulating concentration of the soluble tumor necrosis factor α receptors 1 and 2...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.656928/full |
id |
doaj-1148873a618349bab3442a5f4f3cc44f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexandre Paccalet Claire Crola Da Silva Laura Mechtouff Camille Amaz Yvonne Varillon Charles de Bourguignon Regine Cartier Cyril Prieur Danka Tomasevic Nathalie Genot Simon Leboube François Derimay Gilles Rioufol Eric Bonnefoy-Cudraz Nathan Mewton Nathan Mewton Michel Ovize Michel Ovize Michel Ovize Gabriel Bidaux Thomas Bochaton Thomas Bochaton |
spellingShingle |
Alexandre Paccalet Claire Crola Da Silva Laura Mechtouff Camille Amaz Yvonne Varillon Charles de Bourguignon Regine Cartier Cyril Prieur Danka Tomasevic Nathalie Genot Simon Leboube François Derimay Gilles Rioufol Eric Bonnefoy-Cudraz Nathan Mewton Nathan Mewton Michel Ovize Michel Ovize Michel Ovize Gabriel Bidaux Thomas Bochaton Thomas Bochaton Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction Frontiers in Pharmacology myocardial infarction TNF soluble TNF receptor biomarker prognosis |
author_facet |
Alexandre Paccalet Claire Crola Da Silva Laura Mechtouff Camille Amaz Yvonne Varillon Charles de Bourguignon Regine Cartier Cyril Prieur Danka Tomasevic Nathalie Genot Simon Leboube François Derimay Gilles Rioufol Eric Bonnefoy-Cudraz Nathan Mewton Nathan Mewton Michel Ovize Michel Ovize Michel Ovize Gabriel Bidaux Thomas Bochaton Thomas Bochaton |
author_sort |
Alexandre Paccalet |
title |
Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction |
title_short |
Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction |
title_full |
Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction |
title_fullStr |
Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction |
title_full_unstemmed |
Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction |
title_sort |
serum soluble tumor necrosis factor receptors 1 and 2 are early prognosis markers after st-segment elevation myocardial infarction |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-09-01 |
description |
Background: As inflammation following ST-segment elevation myocardial infarction (STEMI) is both beneficial and deleterious, there is a need to find new biomarkers of STEMI severity.Objective: We hypothesized that the circulating concentration of the soluble tumor necrosis factor α receptors 1 and 2 (sTNFR1 and sTNFR2) might predict clinical outcomes in STEMI patients.Methods: We enrolled into a prospective cohort 251 consecutive STEMI patients referred to our hospital for percutaneous coronary intervention revascularization. Blood samples were collected at five time points: admission and 4, 24, 48 h, and 1 month after admission to assess sTNFR1 and sTNFR2 serum concentrations. Patients underwent cardiac magnetic resonance imaging at 1 month.Results: sTNFR1 concentration increased at 24 h with a median of 580.5 pg/ml [95% confidence interval (CI): 534.4–645.6]. sTNFR2 increased at 48 h with a median of 2,244.0 pg/ml [95% CI: 2090.0–2,399.0]. Both sTNFR1 and sTNFR2 peak levels were correlated with infarct size and left ventricular end-diastolic volume and inversely correlated with left ventricular ejection fraction. Patients with sTNFR1 or sTNFR2 concentration above the median value were more likely to experience an adverse clinical event within 24 months after STEMI [hazards ratio (HR): 8.8, 95% CI: 4.2–18.6, p < 0.0001 for sTNFR1; HR: 6.1, 95% CI: 2.5 –10.5, p = 0.0003 for sTNFR2]. Soluble TNFR1 was an independent predictor of major adverse cardiovascular events and was more powerful than troponin I (p = 0.04 as compared to the troponin AUC).Conclusion: The circulating sTNFR1 and sTNFR2 are inflammatory markers of morphological and functional injury after STEMI. sTNFR1 appears as an early independent predictor of clinical outcomes in STEMI patients. |
topic |
myocardial infarction TNF soluble TNF receptor biomarker prognosis |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.656928/full |
work_keys_str_mv |
AT alexandrepaccalet serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT clairecroladasilva serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT lauramechtouff serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT camilleamaz serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT yvonnevarillon serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT charlesdebourguignon serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT reginecartier serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT cyrilprieur serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT dankatomasevic serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT nathaliegenot serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT simonleboube serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT francoisderimay serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT gillesrioufol serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT ericbonnefoycudraz serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT nathanmewton serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT nathanmewton serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT michelovize serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT michelovize serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT michelovize serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT gabrielbidaux serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT thomasbochaton serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction AT thomasbochaton serumsolubletumornecrosisfactorreceptors1and2areearlyprognosismarkersafterstsegmentelevationmyocardialinfarction |
_version_ |
1717815647095750656 |
spelling |
doaj-1148873a618349bab3442a5f4f3cc44f2021-09-04T00:19:17ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-09-011210.3389/fphar.2021.656928656928Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial InfarctionAlexandre Paccalet0Claire Crola Da Silva1Laura Mechtouff2Camille Amaz3Yvonne Varillon4Charles de Bourguignon5Regine Cartier6Cyril Prieur7Danka Tomasevic8Nathalie Genot9Simon Leboube10François Derimay11Gilles Rioufol12Eric Bonnefoy-Cudraz13Nathan Mewton14Nathan Mewton15Michel Ovize16Michel Ovize17Michel Ovize18Gabriel Bidaux19Thomas Bochaton20Thomas Bochaton21INSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceINSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceStroke Department, Hôpital Wertheimer, Hospices Civils de Lyon, Bron, FranceCentre D’investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FranceCentre D’investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FranceCentre D’investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FranceCentre de Biologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, FranceUnité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, FranceUnité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, FranceUnité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, FranceINSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceDepartment of Interventional Cardiology, Cardiovascular Hospital and Claude-Bernard University, Bron, FranceDepartment of Interventional Cardiology, Cardiovascular Hospital and Claude-Bernard University, Bron, FranceUnité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, FranceINSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceCentre D’investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FranceINSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceCentre D’investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FranceService D’explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FranceINSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceINSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, FranceUnité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, FranceBackground: As inflammation following ST-segment elevation myocardial infarction (STEMI) is both beneficial and deleterious, there is a need to find new biomarkers of STEMI severity.Objective: We hypothesized that the circulating concentration of the soluble tumor necrosis factor α receptors 1 and 2 (sTNFR1 and sTNFR2) might predict clinical outcomes in STEMI patients.Methods: We enrolled into a prospective cohort 251 consecutive STEMI patients referred to our hospital for percutaneous coronary intervention revascularization. Blood samples were collected at five time points: admission and 4, 24, 48 h, and 1 month after admission to assess sTNFR1 and sTNFR2 serum concentrations. Patients underwent cardiac magnetic resonance imaging at 1 month.Results: sTNFR1 concentration increased at 24 h with a median of 580.5 pg/ml [95% confidence interval (CI): 534.4–645.6]. sTNFR2 increased at 48 h with a median of 2,244.0 pg/ml [95% CI: 2090.0–2,399.0]. Both sTNFR1 and sTNFR2 peak levels were correlated with infarct size and left ventricular end-diastolic volume and inversely correlated with left ventricular ejection fraction. Patients with sTNFR1 or sTNFR2 concentration above the median value were more likely to experience an adverse clinical event within 24 months after STEMI [hazards ratio (HR): 8.8, 95% CI: 4.2–18.6, p < 0.0001 for sTNFR1; HR: 6.1, 95% CI: 2.5 –10.5, p = 0.0003 for sTNFR2]. Soluble TNFR1 was an independent predictor of major adverse cardiovascular events and was more powerful than troponin I (p = 0.04 as compared to the troponin AUC).Conclusion: The circulating sTNFR1 and sTNFR2 are inflammatory markers of morphological and functional injury after STEMI. sTNFR1 appears as an early independent predictor of clinical outcomes in STEMI patients.https://www.frontiersin.org/articles/10.3389/fphar.2021.656928/fullmyocardial infarctionTNFsoluble TNF receptorbiomarkerprognosis |